Clinical experiment designed to assess clinical efficacy targeting N/A in human patients undergoing arthroscopic rotator cuff repair. Primary outcome: active forward flexion at 3 months postoperatively
A randomized controlled clinical trial examining the effect of duloxetine on clinical outcomes following arthroscopic rotator cuff repair (ARCR) in patients with anxiety and/or depression" class="entity-link entity-disease" title="disease: Depression">Depression. Patients were categorized into three groups based on Hospital Anxiety and Depression Scale (HADS) scores: group A (healthy psychological status, n=20), group B (psychological distress with duloxetine treatment, n=21), and group C (psychological distress without duloxetine, n=22). Duloxetine was administered orally starting from the evening of surgery at 30 mg/d for 2 weeks, then increased to 60 mg/d for 12 weeks. The study evaluated functional outcomes, structural outcomes, analgesic consumption, and drug-related side effects at multiple time points up to 12 months postoperatively.
Randomized controlled trial with three groups based on HADS scores. Duloxetine administered orally from evening of surgery: 30 mg/d for first 2 weeks, then 60 mg/d for 12 weeks. Assessments at 3, 6, and 12 months postoperatively including range of motion, functional scores (ASES, SST), anxiety scores, pain scores, and opioid consumption.
Improved clinical outcomes, reduced anxiety and depression, better range of motion and functional scores in duloxetine-treated patients with psychological distress compared to untreated controls
Statistically significant improvement in active forward flexion, ASES and SST scores, anxiety scores, and reduced opioid consumption in duloxetine group compared to control group
No related hypotheses
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.